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1 Introduction 1 
1 Introduction 
 
1.1 Fine needle aspiration cytology (FNAC) 
 
Fine needle aspiration cytology (FNAC) is a sufficiently accurate, simple, rapid, 
safe, relatively pain-less and cost-effective technique, rendering it an attractive 
alternative for surgical biopsy Gupta et al. 2006; Kramer et al. 2006; Schafernak et al. 2003; Gupta et al. 
2003a; Nasuti et al. 2000. Surgical procedures instead are invasive, often requiring 
(general) anaesthesia and hospitalization Kramer et al. 2006; Kramer et al. 2004; Young, 2000. It 
is a less invasive method with a lower or similar complication rate compared 
with core needle biopsy. FNAC has been used in the routine diagnosis of 
masses of the liver and it plays an increasingly important role as a first line 
investigation in patients with lymphadenopathy Gupta et al. 2006; De Las Casas et al. 2004 
Yang et al. 2004; Caturelli et al. 2004; França et al. 2003; Soyuer et al. 2003; Schafernak et al. 2003; Caturelli et al. 
2002; Jain, 2002; Hertz et al. 2000; Young, 2000; Dey, 2000; de Boer et al. 1999. An enlargement of a 
lymph node can be caused by reactive hyperplasia, inflammation, metastatic 
malignancy or malignant lymphoma Gupta et al. 2006; Orell et al. 2005. 
 
The specificity and positive predictive value of FNAC in the diagnosis of 
malignant liver lesions has been shown to be close to 100% in the majority of 
studies and the sensitivity of the FNAC procedure ranges between 67% and 
100%, which is similar or better than with core needle biopsy Hertz et al. 2000. Many 
studies reported an increased diagnostic sensitivity with the combination of core 
needle biopsy and FNAC of the liver Caturelli et al. 2004; Jain, 2002; Caturelli et al. 2002. 
 
 
1.2 Liver 
 
Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide in 
terms of newly diagnosed cancer cases (626,000 or 5.7%). Because of the very 
poor prognosis, the number of deaths is nearly the same (598,000), making it 
the third most common cause of death from cancer. Approximately 82% of 
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cases and deaths occur in developing countries (55% reported to occur in 
China alone) Parkin et al. 2005. However, its incidence and mortality have 
substantially increased in the U.S. (United States of America) and the U.K. 
(United Kingdom) in the last 20 years of the 20th century West  et al. 2006; El-Serag & 
Mason 1999.  
 
The vast majority of malignancies in the liver are metastatic adenocarcinomas. 
In the majority of these cases, the patients have a known history of a primary 
tumor elsewhere. However, some patients do not demonstrate a known primary 
tumor (carcinoma of unknown primary). Cells or tissues from liver metastases 
can give hints to the site of the primary tumor. Furthermore, a distinction 
between primary and metastatic tumors needs to be made Centeno, 2006; Jain, 2002. 
HCC is the most common primary cancer of the liver, usually developing in the 
setting of chronic liver disease, particularly viral hepatitis Kramer, 2004. The 
differential diagnosis of HCC versus metastatic carcinoma is clinically important 
because prognosis and treatment approaches are different Wang et al. 2006; Saad et al. 
2004; Zimmerman et al. 2002; Zimmerman et al. 2001.  
 
The main difficulties with cytologic diagnoses of coin lesions of the liver are 
distinguishing HCC from other carcinomas and identifying primary tumor sites 
from their liver metastases Centeno, 2006; França et al. 2003. These problems may be 
overcome by the application of immunocytochemical panels that can be 
selected on the basis of the likelihood of suspected diagnoses, using a problem 
oriented approach Centeno, 2006; Dabbs & Wang 1998.  
 
 
1.3 Lymph nodes 
 
Metastatic tumors represent the majority of findings in the FNAC of enlarged 
lymph nodes Schafernak et al. 2003; Gupta et al. 2003b; Nasuti et al. 2000. Once the diagnosis of 
metastatic malignancy is established, the question of the primary tumor arises 
to provide the basis of an appropriate treatment. In most cases, the primary 
tumor is clinically known. Yet, when the primary tumor is unknown, FNAC can 
focus the search for its site of origin. Some carcinomas can be identified by their 
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cytomorphological characteristics alone Kocjan, 2006; Orell et al. 2005. However, there 
are many instances where features of different tumors overlap and the precise 
diagnosis of a primary tumor remains obscure. Ancillary laboratory techniques 
such as immunocytochemistry are used to overcome these difficulties and 
support the cytodiagnostic interpretation Gupta et al. 2006; De Las Casas et al. 2004; Gupta et al. 
2003a; Gupta et al. 2003b; Nasuti et al. 2000. Immunocytochemical marker panels can be 
selected on the basis of the likelihood of suspected diagnoses, using a problem 
oriented approach Dabbs, 2006; Varadhachary et al. 2004; Bugat et al. 2003. 
 
 
1.4 Immunocytochemistry 
 
Various ancillary methods, as immunocytochemistry have been used on FNAC 
to further improve the diagnostic accuracy. Although the majority of 
investigations in the literature were performed on cell block material, 
immunocytochemistry can also be performed directly on smeared and even 
prestained cells.  
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2 Material and Methods 
 
2.1 Case selection 
 
Between 2001 and 2004, 548 FNACs of the liver (Fig. 1) and 984 FNACs of 
lymph nodes (Fig. 2) from the University Hospital of Duesseldorf and from 
hospitals of the surrounding area were routinely investigated in the Institute of 
Cytopathology, Heinrich Heine University Duesseldorf.  
 
 
Figure 1: Flow chart illustrating the progress of subjects through the validating cohort study of 
FNAC of the liver. FNACs indicates fine-needle aspiration cytologies; HCC = hepatocellular 
carcinoma; CUP = carcinoma of unknown primary. 
548 FNACs of liver
Unsatisfactory
n=38 (6.9%)
Satisfactory
n=510 (93.1%)
Negative n=164 (32.2%)
Doubtful and
Suspicious n=42 (8.2%)
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n=304 (59.6%)
Immunocytochemistry
n=122
- Unknown Primary
- HCC 
No Immunocytochemistry
- Known Primary
n=87 (47.8%)
- Technical Problem 
n=95 (52.2%)
Follow up
n=108 (88.5%)
No Follow up
n=14 (11.5%)
HCC
n=23
Accuracy 100%
Metastatic
Carcinomas
n=85
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Found (CUP)
n=23 (27.1%)
Primary Tumor Found
n=62
Accuracy 90.3%
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Figure 2: Flow chart illustrating the progress of subjects through the validating cohort study of 
FNAC of lymph nodes. FNACs indicates fine-needle aspiration cytologies; LN = lymph nodes. 
 
In 38 cases (6.9%) of FNACs of the liver and in 218 cases (22.2%) of lymph 
nodes, the cytologic diagnoses were unsatisfactory due to none or scanty 
number of cells. A total of 164 cases (32.2%) and 401 cases (52.4%) were 
negative for malignancy and 42 (8.2%) and 93 (12.1%) doubtful or suspicious 
from FNACs of the liver and lymph nodes, respectively. A total of 304 cases 
were diagnosed as positive for malignant cells from FNACs of the liver, and 272 
cases from FNACs of lymph nodes. 182 cases from FNAC of the liver and 198 
cases from FNAC lymph nodes were excluded from the current study because 
the clinicians knew the primary site of the metastatic tumors in 87 cases 
(47.8%) and respectively in 138 cases (69.7%) and/or immunocytochemistry 
could not be performed in 95 (52.2%) and respectively in 60 (30.3%) due to air 
drying, small number of atypical cells, excess of blood and/or necrotic cells. 
Fourteen cases with FNACs of the liver and 10 with lymph nodes were excluded 
from the investigation because no follow-up information was available. 
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No Immunocytochemistry 
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- Technical Problem 
n= 60 (30.3%)
No Follow up
n=10 (13.5%)
Follow up
n=64 (86.5%)
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(n=8)
Accuracy 
87.5%
Differential 
Diagnosis
(n=10)
Accuracy 
100%
Unknown 
Primary
(n=30)
Accuracy 
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2 Materials and Methods  6 
Biopsy histology as a reference standard of follow up was obtained in 55.6% of 
patients that were submitted for FNACs of the liver, whereas computer 
tomography and ultrasound were applied in 69.5% and 79.6% of patients, 
respectively (Table 1). For patients submitted for FNACs of lymph nodes, 
biopsy histology was obtained in 60.9%, whereas computer tomography was 
applied in 76.6% and ultrasound in 86% of patients (Table 2). 
 
Table 1: Reference standards for 108 FNACs of the liver.  
 HCC (n=23) Primary Tumor Sites (n=85) Total(n=108) 
Biopsy (alone) 1 (4.4%) 7 (8.2%) 8 (7.4%) 
CT (alone) - 4 (4.7%) 4 (3.7%) 
US (alone) 5 (21.7%) 8 (9.4%) 13 (12%) 
Biopsy + CT 1 (4.4%) 9 (10.6%) 10 (9.3%) 
Biopsy + US 3 (13%) 9 (10.6%) 12 (11.1%) 
Biopsy + CT+ US 5 (21.7%) 25 (29.4%) 30 (27.8%) 
CT + US 8 (34.8%) 23 (28.7%) 31 (28.7%) 
FNACs indicates fine-needle aspiration cytologies; HCC = hepatocellular carcinoma; CT = 
computer tomography; US = ultrasound sonography 
 
Table 2: Reference standards for 64 FNACs of lymph nodes.  
 Confirmatory 
(n=16) 
Differential 
Diagnosis 
(n=10) 
Lymphoma 
Typing   
(n=8) 
Primary 
Tumor Site 
(n=30) 
Total 
(n=64) 
Biopsy (alone) - - 1 (12.5%) - 1 (1.6%) 
CT (alone) 1 (6.3%) - 3 (37.5%) - 4 (6.3%) 
US (alone) 2 (12.5%) - - 3 (10%) 5 (7.8%) 
Biopsy + CT 1 (6.3%) 1 (10%) 1 (12.5%) 1 (3.3%) 4 (6.3%) 
Biopsy + US 1 (6.3%) 2 (20%) 1 (12.5%) 5 (16.7%) 9 (14%) 
Biopsy + CT+ 
US 
6 (37.5%) 3 (30%) 2 (2.5%) 14 (46.7%) 25 (39%) 
CT + US 5 (31.1%) 4 (40%) - 7 (23.3%) 16 (25%) 
FNACs indicates fine-needle aspiration cytologies; HCC = hepatocellular carcinoma; CT = 
computer tomography; US = ultrasound sonography 
 
The present prospective study was performed on 108 FNACs of the liver and on 
64 FNACs of lymph nodes with cytologic and immunocytochemical diagnoses 
that were confirmed by histologic and/or clinical follow-up. In 23 cases with 
FNACs of the liver we tried to differentiate between HCCs and metastatic 
carcinomas or regenerative nodules. 85 FNACs were used to identify primary 
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tumor sites. The median age of patients with FNACs of the liver was 68 years 
(range, 42-88 years) and the male:female ratio, 76:32. In the cases of FNACs of 
lymph nodes, the sites of a primary tumor metastatic to the lymph nodes or a 
malignant lymphoma were unknown to the clinicians. In 10 cases the 
differentiation of Non Hodgkin Lymphoma from a metastatic carcinoma was 
requested, in 30 the identification of primary tumor sites, in 8 the classification 
of NHL, and in 16 cases the confirmation of a clinical suggestion of a specific 
primary tumor. The median age of patients with FNACs of lymph nodes was 64 
years (range, 30-90 years) and the male:female ratio, 33:31. 
 
Liver and lymph node FNACs were performed by clinicians using computed 
tomography or ultrasound guidance and a 22-gauge spinal needle. The majority 
of nodes aspirated were from the mediastinum (Table 3).The aspirated material 
was smeared immediately onto 4-40 (mean 13) glass slides from FNACs of the 
liver and onto 2-29 (mean 12) from lymph nodes and fixed with Merckofix-spray 
(Merck, Darmstadt, Germany). All specimens were stained according to 
Papanicolaou. Immunocytochemistry was performed on the identical stained 
slides used for cytologic diagnosis Pomjanski et al. 2005. Slides were uncovered in 
xylene at room temperature for immunocytochemistry staining. The coverslips 
fell off within 24 hours. If there were not enough slides from a patient to apply 
six different antibodies, the slides were divided into two or three regions using a 
DakoPen (Dako, Glostrup, Denmark, no. S2002). Thus that more than one 
antibody could be applied simultaneously on the same slide. 
 
Table 3: Sites of punctuated lymph nodes. 
Lymph node No. of cases Percentage 
Mediastinum 24 37.5% 
Cervical 8 12.5% 
Paraaortal 5 7.8% 
Paraoesophageal 5 7.8% 
Abdominal 2 3.1% 
Supraclavicular 2 3.1% 
Miscellaneous 6 9.4% 
Not specified 12 18.8% 
2 Materials and Methods  8 
2.2 Antibodies 
 
Table 4 provides the characteristics, dilutions, pre-treatments, and providers of 
different antibodies used.  
 
Table 4: Antibodies, clones, dilutions, pre-treatments and providers.  
Antibody Clone Dilution Pre-treatment Provider 
HepPar1 OCH1E5 1:50 None Dako 
-Fetoprotein C3 1:50 None Novocastra 
CD31 JC-70A 1:50 None Dako 
CD68 PG-M1 1:600 None Dako 
Ki-67 MIB 1 1:150 Citrate buffer, ph 6.0 Dianova 
TTF-1 8G7G3/1 1:200 Citrate buffer, ph 6.0 Acris 
CdX2 CDX2-88 1:5000 Citrate buffer, ph 6.0 BioGenex 
Melan A A103 1:50 None Dako 
BerEP4 BerEP4(1) 1:200 None Dako 
Chromogranin A DAK-A3 1:2500 None Dako 
Synaptophysin SY38 1:100 None Dako 
LCA 2B11 + PD7/26 1:1500 None Dako 
CD56 ERIC-1 1:400 None Novocastra 
CD20 L26 1:400 None Dako 
CD15 C3D-1 1:1000 None Dako 
CD79 JCB117 1:100 None Dako 
CD45Ro UCHL1 1:400 None Dako 
CD30 Ber-H2 1:200 None Dako 
BCL-2 124 1:75 None Dako 
PSA ER-PR8 1:200 None Dako 
RCC 66.4.C2 1:50 None Novocastra 
S100 Anti-S100 1:5800 None Dako 
HMB-45 HMB45 1:400 None Dako 
CA15-3 DF3 1:100 None Dako 
CD138 MI15 1:100 None Dako 
Uroplakin III AU1 1:10 None Innovative 
Diagnostik-System 
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In the cases of FNACs of the liver, to differentiate HCCs from metastatic 
carcinomas or regenerative nodules, we applied a panel consisting of HepPar1, 
-Fetoprotein, BerEP4, CD31, CD68 and Ki-67. To identify the primary sites of 
metastatic carcinomas, we applied a panel comprising CK5/6, CK7, CK20, 
CA125, TTF-1 and Cdx2. Depending on the clinical suspicion, we used other 
antibodies in individual cases. When a clinician suspected for example a 
neuroendocrine neoplasia, we used chromogranin A, vimentin if renal cancer 
was suspected, oestrogen receptor if breast cancer was suspected or prostate-
specific antigen (PSA) if prostate cancer was suspected. For the differential 
diagnosis between small cell carcinoma and lymphoma, LCA was applied. 
 
In the cases of FNACs of lymph nodes, to differentiate NHL from metastatic 
carcinoma, we applied BerEp4 and LCA. To identify the primary sites of 
metastatic carcinomas, we applied a panel consisting of CK5/6, CK7, CK20, 
CA125, TTF-1 and Cdx2. When there was a cytological and/or clinical 
suspicious for a neuroendocrine tumor, we applied BerEP4, LCA, TTF1, CD56, 
Chromogranin A and Synaptophysin staining. We used Melan A to confirm 
malignant melanoma. To classify lymphomas, we performed staining for LCA, 
CD20, CD79a, CD45Ro, CD15 and CD30. To confirm a clinical suspicion of a 
specific tumor site, we performed PSA when suspected of metastatic prostate 
cancer, CD138 when suspected of plasmocytoma, RCC when suspected of 
metastatic renal cell carcinoma, LCA to exclude or confirm lymphoma, 
Uroplakin III when suspected of bladder carcinoma, S100 and HMB-45 to 
identify malignant melanoma, CA15-3 e.g. for suspicion of breast cancer, and 
Chromogranin A and Synaptophysin to identify a neuroendocrine tumor.  
 
 
2.3 Immunocytochemistry 
 
The avidin-biotin complex method (ABC) was applied for visualization of 
immunologic reactions. All steps were performed according to previous study 
Motherby et al. 1999. Apart from the fact that all of our antibodies were originally tested 
with tumor-positive and -negative effusions, we did not apply positive and 
negative controls on separated slides routinely due to scarcity of smears. 
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Normal macrophages, lymphocytes, and granulocytes were usually used for 
internal negative control. Incubations were performed with commercially 
available monoclonal primary antibodies (Table 4) followed by a biotinylated link 
antibody and the ABC-Elite Standard (Vector Laboratories, Burlingame, Calif). 
To our knowledge, unspecific staining due to endogenous biotin has only been 
reported to date in liver tissue sections Iezzoni et al. 1999; Bussolati et al. 1997, but not in 
alcohol fixed cells. After finding no difference between alcohol fixed liver cells 
with or without blocking of potential endogenous biotin, we discontinued its 
application in our routine immunocytochemistry. The substrate chromagen 
reagent was 3-amino-9-ethylcarbazole (AEC). Counterstaining needed for the 
recognition of cells was performed with Mayer haematoxylin. 
 
 
2.4 Microscopic Evaluation 
 
The cytologic examinations were performed by two experienced 
cytopathologists working together to a final diagnosis. Accepted 
cytomorphological criteria Kocjan, 2006; Orell et al. 2005; Soyuer et al. 2003; Jain, 2002; Das, 1999 
were used to choose the adequate immunocytochemical panel. For diagnostic 
interpretation of immunocytochemical staining, we used a subjective, 
semiquantitative evaluation scheme based on the frequency of stained tumor 
cells (Fig. 3). Staining intensity per cell was not evaluated because it depends 
too much on the different variables of the staining process. The results were 
given as scores per slide (Fig. 3). 
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Figure 3: Semi quantitative evaluation of immunocytochemical staining.  
 
 
2.5 Diagnostic accuracy 
 
The accuracy of the combined cytomorphologic and immunocytochemical 
diagnoses was defined as the percentage of correctly classified HCCs or 
lymphomas or correct locations of primary tumors.  
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3 Objectives 
 
The objective of the current validating cohort study was to analyse the 
performance of a panel of six monoclonal antibodies (HepPar1, -Fetoprotein, 
BerEP4, CD31, CD68 and Ki-67) for the differentiation of HCC from metastatic 
carcinoma or regenerative nodules in FNACs of the liver. A second panel 
(CK5/6, CK7, CK20, CA125, TTF-1 and Cdx2) was used to identify the primary 
sites of metastatic carcinomas in FNACs of the liver and also in lymph nodes. In 
FNACs of lymph nodes we analysed the performance of a third panel (BerEP4, 
LCA, TTF1, CD56, Chromogranin A and Synaptophysin) when there was a 
cytological and/or clinical suspicious for a metastatic neuroendocrine tumor. 
Applying BerEp4 and LCA, we differentiated Non Hodgkin lymphoma (NHL) 
from metastatic carcinoma. Using different antibodies (PSA, CD138, RCC, LCA, 
Uroplakin III, S100, HMB-45, CA15-3, Chromogranin A and Synaptophysin), we 
tried to confirm the clinical suspicion of a specific primary tumor site. Finally, we 
tried to classify malignant lymphomas applying LCA, CD20, CD79a, CD45Ro, 
CD15 and CD30. 
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4 Results 
 
Diagnostic accuracy of FNAC applying adjuvant immunocytochemistry was 
investigated by correlation of cytologic diagnoses with histological and/or clinical 
follow up to differentiate hepatocellular carcinomas (HCC) from metastatic 
carcinomas or regenerative nodules in FNACs of the liver, to identify the 
primary tumor sites of metastatic carcinomas in FNACs of the liver and lymph 
nodes, to differentiate Non Hodgkin lymphoma (NHL) from metastatic 
carcinoma, to confirm a clinical suspicion of a specific primary tumor site and 
classify lymphomas in FNACs of lymph nodes.  
 
In FNACs of the liver, HepPar1 was positive with scores > 2 in all HCCs (83% of 
which demonstrated scores > 4), but negative in all metastatic carcinomas 
(score 0) with exception of 1 cholangiocarcinoma that exhibited few cells (score 
2) with granular cytoplasmic staining (Table 5). Although BerEP4 was found to 
be positive in a few cells (score 1) in only 33% of HCCs, this marker was 
positive in all metastatic carcinomas. One malignant melanoma was completely 
negative for that marker (score 0). -Fetoprotein was positive in 62% of HCCs 
with scores > 2, but was negative in all metastatic carcinomas (score 0). Strong 
CD 31 positivity in endothelial cells transgressing and surrounding tumor cells 
was observed in HCCs only, not in metastatic carcinomas. CD68 positivity was 
not observed in HCCs (score 0). 89.5% of HCCs revealed > 30% of Ki-67 
positive cells. 
 
Table 5: Typical immunoreactivity of HCCs using a panel of six antibodies to differentiate them 
from metastatic carcinomas or regenerative nodules. 
 
Marker Expression 
HepPar1  score > 2 
-Fetoprotein score > 2 
Ki-67 > 30% positive 
BerEP4 negative 
CD 31 endothelial staining 
CD 68 negative 
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Based on these results, we established an algorithm for the diagnostic 
interpretation of immunocytochemical staining results to differentiate HCCs from 
metastatic carcinoma or regenerative nodules in FNACs of the liver (Fig. 4). 
Typing accuracy of FNAC applying immunocytochemistry to differentiate HCC 
from metastatic carcinoma or regenerative nodules in 23 patients was 100%. All 
cytological diagnoses of HCC were confirmed either histologically or by clinical 
follow up (Table 1).  
 
HepPar1 BerEP4
HepPar1     > 2
BerEP4       < 1
Metastatic Carcinoma 
Panel (fig.3)
Lungs Ovaries Colon
HepPar1     = 0
BerEP4       > 2
AFP         > 2
Ki67        > 30%
CD68      neg
CD31      pos
Stomach
PancreasHCC
 
Figure 4: Algorithm for differentiating HCCs from metastatic carcinomas or regenerative nodules 
in FNACs of the liver. The results of HepPar1, BerEP4 and -Fetoprotein (AFP) staining were 
given as scores (see Fig. 1); Ki-67 results were expressed in percentage of positive cells. neg 
indicates negative; pos = positive. HepPar1 = hepatocyte paraffin-1; BerEP4 = surface and 
cytoplasmic glycoprotein marker; AFP (-Fetoprotein) = fetal protein; Ki-67 = proliferation 
marker; CD31 = platelet-endothelial cell adhesion molecule-1; CD68 = macrophage marker. 
 
 
The immunoreactivity patterns observed in liver metastases from different 
primary tumor sites were observed as follows (Tables 6 and 7). 
 
Carcinomas of the colon 
Most metastatic cells of colon carcinomas demonstrated strong positivity with 
Cdx2 (score 5). Numerous cells were positive with CK20 (score > 3). No 
staining was observed with CK5/6, CA125 and TTF-1 (score 0). Approximately 
91.7% of metastatic colon adenocarcinomas to the liver had CK20 scores > 
CK7, but all patients demonstrated CK20 positivity. Cdx2 was positive in 85.7% 
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of metastases from colon carcinomas with score >2 and 67% demonstrated 
showed strong positivity (score 5). 
 
Table 6: Typical semiquantitative immunoreactivity of metastatic carcinomas of most common 
primary sites confirmed by follow up using a panel of six antibodies, presented as scores. 
 
Carcinoma of 
Immunocytochemical Marker 
CK5/6 CK7 CK20 CA125 TTF-1 Cdx2 
Colon (n=16) 0 0 3 0 0 5 
Lungs (n=10) 0 5 1 0 2 1 
Bile ducts (n=5) 0 5 3 0 0 0 
Gastrointestinal (n=5) 3 4 3 0 0 2 
Pancreas (n=4) 1 5 4 0 0 0 
 
 
Carcinomas of the lungs 
The majority of metastatic cells from carcinomas of the lungs demonstrated 
strong CK7 positivity (score 5). Only a few cells revealed reaction with CK20, 
TTF-1 and Cdx2 (scores > 1, 2 and 1, respectively). CK 5/6 and CA125 were 
found to be negative in all cases. A CK7 score > CK20 score was found in all 
cases, and TTF-1 (score > 2) was positive in 50% of cases. 
 
Cholangiocarcinomas 
Metastatic cells from cholangiocarcinomas demonstrated a diffuse positivity with 
CK7 (score 5). Numerous cells were positive for CK20 (score > 3). CK5/6, 
CA125, TTF-1 and Cdx2 (score 0) were completely negative. CK7 score > the 
CK20 score was found in all cholangiocarcinomas. 
 
Other gastrointestinal carcinomas 
The typical marker constellation for gastrointestinal carcinomas was: CK5/6 
score > 3, CK7 score > 4, CK20 score > 3, CA125 score 0, TTF-1 score 0 and 
Cdx2 score 2. CK5/6 was found to be positive in 50%.  
 
Carcinomas of the pancreas 
Metastatic carcinomas of the pancreas demonstrated a constellation that was 
very similar to that of metastatic cholangiocarcinomas; the majority of cells were 
positive for CK7 (score 5), many demonstrated positivity for CK20 (score > 4), 
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few were positive for CK5/6 (> score 1) and no reactions were observed with 
CA125, TTF-1 and Cdx2 (score 0). A CK7 score > that of CK20 was found in all 
cases. CK5/6 (score 1) was weakly positive in 50% of cases.  
 
Other carcinomas 
The semiquantitative evaluation of immunoreactivity of metastatic tumors from 
less common sites is shown in Table 7. We could not apply all antibodies of the 
panel described above in all of these patients due to limited number of smears. 
 
Table 7: Semiquantitative immunoreactivity of metastatic carcinomas in less common sites 
confirmed by follow up using a panel of six antibodies in nine patients with FNACs of the liver 
presented as scores. 
 
Carcinoma of 
Immunocytochemical Marker 
CK5/6 CK7 CK20 CA125 TTF-1 Cdx2 
Breast 1 - 0 - - 0 
Breast 4 5 1 0 0 2 
Breast 4 5 1 - - - 
Kidney - - 0 - - - 
Kidney - 0 0 - - - 
Kidney - 2 3 - - - 
Urinary - 2 1 - - 1 
Ovaries - 5 0 4 - 0 
Prostate - 1 1 - - 0 
 
 
In three cases, metastatic neuroendocrine tumors demonstrated positivity in 
most cells with chromogranin A and synaptophysin (score > 4). In two cases of 
malignant melanoma, the majority of metastatic cells revealed positivity with 
HMB-45 (score 5). PSA was positive (score > 3) in one case of prostate 
carcinoma. In one case of angiosarcoma of the liver, endothelial cells 
demonstrated positivity for CD31. 
 
Based on these results, we established an algorithm to identify the origin of 
metastatic carcinomas in FNACs of the liver (Fig. 5). In 23 cases (27.1%), the 
primary tumor remained clinically unknown. The accuracy to correctly identify 
the primary site of metastatic carcinomas in 62 patients was 90.3%. In six cases 
(not demonstrated as a table) our results were not corroborated by follow up. 
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These cases included one cholangiocarcinoma, one HCC, one lung tumor, one 
gastro-intestinal tumor, one renal carcinoma; and one malignant melanoma.  
 
CK 7 CK 20
CK7 = CK 20
CK 5/6
CK7 > CK 20 CK7 < CK 20
TTF1
Cdx2CA125
Cdx2 Cdx2
Lungs Ovaries Stomach
Pancreas
GI 
Tract
> 2 > 3
0-1
4
3
1-2
&
 
Figure 5: Algorithm for identification of the most primary sites of metastatic carcinomas in 
FNACs of the liver and lymph nodes. The results are given as scores. CK indicates cytokeratin; 
CA125 = cancer antigen 125; TTF1 = thyroid transcription factor 1; Cdx 2 = intestine-specific 
homeobox gene.  
 
The immunocytochemical panel for the identification of so far unknown primary 
sites of metastatic carcinomas achieved its best results identifying tumors of the 
colon and the lungs (both correct in 100%). All four cases of carcinomas of the 
pancreas were also correctly identified. 
 
To differentiate NHL from metastatic carcinoma, we applied BerEP4 and LCA 
(also called CD45) in ten FNACs of lymph nodes. Two cases remained as 
unknown primaries even after clinical follow up with computer tomography and 
ultrasound. In all seven cases of metastatic carcinomas, BerEP4 was positive 
(score > 2) and LCA negative (score 0). In one case of NHL, BerEP4 was 
negative (score 0) and LCA positive (score 5). Diagnostic accuracy of FNAC 
applying immunocytochemistry to differentiate NHL from metastatic carcinoma 
in eight patients was 100%. 
 
The immunoreactivity patterns observed in lymph node metastases from 
different primary tumor sites, from 19 patients were as follows (Table 8). 
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Table 8: Typical semiquantitative immunoreactivity of metastatic carcinomas from different sites 
using a panel of six antibodies in FNACs of lymph nodes, presented as scores  
 
Carcinoma of 
Immunocytochemical marker 
CK5/6 CK7 CK20 CA125 TTF-1 Cdx2 
Lungs (n=8) 1 4 2 0 2 0 
Intestines (n=3) 0 0 5 0 0 5 
Oesophagus (n=1) 0 0 2 0 0 1 
Cholangiocarcinoma (n=1) 2 2 1 - - - 
Cervix (n=1) 1 4 1 - - - 
 
 
Carcinomas of the lungs 
Many metastatic cells from carcinomas of the lungs demonstrated CK7 positivity 
(score > 4). Considerable number of tumor cells revealed reaction with CK20 
and TTF-1 (scores > 2). A CK7 score > CK20 score was found in all cases. 
TTF-1 (score > 2) was positive in 66.7% of cases. Cdx2 and CA125 were 
negative in all cases, with the exception of only one case CA125 was positive 
(score 4) and TTF-1 negative, therefore we assumed an ovarian carcinoma but 
the histological and clinical follow up (based on computer tomography and 
ultrasound) rendered a metastatic lung cancer. 
 
Carcinomas of the intestines 
In all three cases (1 jejunum carcinoma and 2 rectum carcinomas), the majority 
of the metastatic cells demonstrated strong positivity with Cdx2 and CK20 
(score 5). No staining was observed with CK7, CK5/6, CA125 and TTF-1 (score 
0).  
 
Carcinoma of the Oesophagus 
In one case of metastatic oesophageal carcinoma, tumor cells demonstrated 
positivity with CK20 (score 2) and Cdx2 (score 1). CK5/6, CK7, CA125 and 
TTF-1 were found to be negative (score 0).  
 
Cholangiocarcinoma 
Metastatic cells from one cholangiocarcinoma demonstrated positivity with CK7 
(score 2), CK20 (score 1) and CK5/6 (score 2). Other markers were not used 
because of a limited number of smears. 
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Carcinoma of the uterine cervix 
Many squamous carcinoma cells demonstrated positivity with CK7 (score 4). 
Only a few cells demonstrated positivity for CK5/6 and CK20 (score 1). Other 
markers were not applied because of a limited number of smears. 
 
In three cases using this panel (15.8%), the primary site remained clinically 
unknown. In one case of malignant melanoma, CK7, CK20, CK5/6, TTF1, 
CA125 demonstrated no positivity, Cdx2 had positivity in few cells (score 1), 
and Melan A demonstrated high positivity (score 4). In one case, our result was 
not corroborated by follow up. It was a lung carcinoma that we assumed to be 
an ovarian carcinoma as a consequence of the immunocytochemical marker 
staining described above.  
 
The applied panel of monoclonal antibodies used for 11 patients with 
cytomorphological suspicion of metastatic neuroendocrine tumors demonstrated 
positivity in a considerable number of cells with BerEP4, TTF1, chromogranin A 
and synaptophysin (score > 2) and numerous cells with CD56 (score > 3) in all 
cases, with exception of TTF1 that was positive in 71.4% of cases. The 
cytomorphological criteria used to suspect a metastatic neuroendocrine were: 
hypercelularity with loose to tight clusters of small cells with high 
nuclear/cytoplasm ratio and practically no visible cytoplasm; finely granular and 
diffuse chromatin pattern with inconspicuous nucleoli; nuclear molding, and 
necrotic background Orell et al. 2005; Gupta et al. 2003b. No staining was observed with 
LCA (score 0) in all cases (Table 9). One case continued as unknown primary 
site carcinoma after clinical follow up (computer tomography and ultrasound). In 
one case, we assumed a neuroendocrine tumor, yet histology and clinical follow 
up rendered a bile duct carcinoma grade 3. 
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Table 9: Typical immunoreactivity using a panel of six antibodies to identify neuroendocrine 
tumors. 
 
Marker Expression 
BerEP4 > 2 
LCA 0 
TTF1 > 2 
CD56 > 3 
Chromogranin A > 2 
Syaptophysin > 2 
 
 
Diagnostic accuracy of FNAC of lymph nodes applying immunocytochemistry in 
30 patients to identify the primary site of metastatic carcinomas was 92.3%. 
Based on these results, we established an algorithm to identify the location of 
metastatic carcinomas, as previously described Pomjanski et al. 2005, also for FNACs 
of lymph nodes (Fig. 5) and another one when there was a cytomorphological or 
clinical indication for the presence of a neuroendocrine tumor (Fig. 6). 
 
LCABerEP4
BerEP4    > 2
LCA         0
Lymphoma
TTF1                    > 2
CD56                   > 3
Chromogranin A  > 2
Synaptophysin     > 2
Neuroendocrine 
Tumor
BerEP4   0
LCA         > 3
&
 
Figure 6: Algorithm for identification of metastatic neuroendocrine tumors in FNACs of lymph 
nodes. The results are presented as scores. LCA indicates leucocyte common antigen; TTF1 = 
thyroid transcription factor 1; CD56 = neural cell adhesion molecule.  
 
 
To classify malignant lymphomas, we used LCA to confirm this diagnosis that 
demonstrated positivity in numerous lymphatic cells (score > 3). To type a NHL 
as B-cell in origin, CD20 was positive in many lymphatic cells (score > 4) and 
CD79a in numerous cells (score > 3). In two cases, we used CD45Ro as a T-
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cell marker that revealed no reaction (score 0). In one suspected case of 
Hodgkin lymphoma, we applied CD15 and CD30 that both showed high 
positivity (score 4), but the histologic and clinical follow up rendered a NHL.  
 
Diagnostic accuracy of FNAC of lymph nodes in eight patients applying 
immunocytochemistry to classifying was 87.5%. In one case (12.5%), we 
assumed a Hodgkin disease, yet histology and clinical follow up (computer 
tomography and ultrasound) rendered a NHL. 
 
To confirm the clinical suspicion of a metastatic carcinoma, we used different 
markers according to the respective clinicians proposal. In three cases of a 
neuroendocrine tumor, CD56 demonstrated positivity in many cells (score 4) 
and TTF1 in some cells (score > 2). In three cases of Non Hodgkin lymphoma, 
Ki-67 was positive in > 50% of cells and BCL-2 in a considerable number of 
cells (score 2). In two cases of prostate carcinoma, PSA demonstrated positivity 
in a considerable number of cells (score > 2). In one case of plasmocytoma, 
CD138 was positive in the majority of the cells (score 5). In one case of renal 
cell carcinoma, RCC was positive in some cells (score 2). In one case of 
bladder carcinoma, Uroplakin III was positive in some cells (score 2). In one 
case of a malignant melanoma, S100 and HMB-45 demonstrated positivity in a 
considerable number of cells (score 2). In one case of breast carcinoma, CA15-
3 was positive in the majority of the cells (score 5). In one case of squamous 
cell carcinomas of the lung , CK7 and CK1,10,11 were positive in the majority of 
the cells (score 5), CK20 and TTF1 were negative (score 0). In one case of 
pancreatic carcinoma, BerEP4 was positive in the majority of the cells (score 5) 
and negative for LCA, chromogranin A and synaptophysin (score 0). 
 
Diagnostic accuracy of FNAC of lymph nodes applying immunocytochemistry to 
confirm a clinically suspected carcinoma in 16 patients was 100%. One case 
(6.3%) continued as carcinoma of unknown primary site even after clinical 
follow up (computer tomography and ultrasound). 
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5 Discussion 
 
The diagnostic evaluation of liver masses and enlarged lymph nodes by FNAC 
is an accepted, safe and effective diagnostic procedure Gupta et al. 2006; Kramer et al. 
2006; Caturelli et al. 2004; Yang 2004; França et al. 2003; Soyuer et al. 2003; Schafernak et al. 2003; Gupta et al. 
2003a; Caturelli et al. 2002; Jain, 2002; Nasuti et al. 2000; de Boer et al. 1999; Hertz et al. 2000. FNAC has 
been used in the routine diagnostic workup of masses of the liver due to various 
advantages in comparison with core needle biopsy Yang 2004; Hertz et al. 2000. FNAC 
smears can be rapidly stained and examined. It is the first choice for deep-
seated and difficult-to-reach lesions. Cost analysis also has demonstrated that 
FNAC is cheaper than core needle biopsy Saad et al. 2004. FNAC has been used 
also in the routine diagnostic workup of lymphadenopaties due to various 
advantages in comparison with surgical biopsy Kramer et al. 2006; Young, 2006; Kramer et al. 
2004. 
 
However, distinguishing HCC from metastatic carcinoma may pose a challenge, 
particularly if the tumor is poorly differentiated. Moreover, the treatment and 
prognosis of HCC and metastatic carcinoma are significantly different. The 
ability to distinguish primary from metastatic malignancy of the liver is clinically 
important Saad et al. 2004; Zimmerman et al. 2001. In FNAC of the lymph nodes, there are 
also some cytomorphological features that overlap between different 
lymphomas and carcinomas, making the diagnosis difficult. The application of 
adjunct diagnostic tools, such as immunocytochemical staining, is therefore 
sometimes essential for a definitive diagnosis in those cases. 
 
We investigated a panel of six monoclonal antibodies to differentiate HCC from 
metastatic carcinoma or regenerative nodules (Fig. 4) in 23 FNACs of the liver 
confirmed by histology and/or clinical follow up and found a correct diagnosis in 
100% of the cases.  
 
To differentiate HCC from metastatic carcinoma or regenerative nodules, we 
tested an algorithm analysing HepPar1 and BerEP4 reactions. When HepPar1 
was positive (score > 4) and BerEP4 negative (score 0), we favoured an HCC. 
To reinforce this diagnosis, we awaited -Fetoprotein (score > 2), Ki-67 in > 
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30% tumor cells positive, CD68 negative and CD31 positive endothelial cells. 
HCCs cells are typically transgressed and surrounded by CD31 positive 
endothelial cells of capillaries (Fig. 7); however, this is not the case in 
metastatic carcinomas. When BerEP4 was positive (score > 2) and HepPar1 
was negative, we favoured a metastatic carcinoma and applied the 
immunocytochemical panel for tumors of unknown primary (Fig. 5). When CD68 
was positive, Ki-67 expressed in < 2% of hepatic cells Quaglia et al. 2006 and CD31 
was negative (Fig. 8), we favoured a benign nodule. 
 
 
Figure 7: HCCs cells stained by CD31 showing transgressed and surrounding positivity in 
capillaries (100X).  
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Figure 8: Hepatic cells from regenerative nodules stained by CD31, showing no staining (100X).  
 
HepPar1 recognizes a specific epitope that is a component of hepatocellular 
mitochondria, resulting in a granular cytoplasmic staining Lugli et al. 2004; Zimmerman et 
al. 2001. Many authors reported on the immunoreactivity spectrum of HepPar1 in 
formalin-fixed tissue from a variety of neoplasms. Lugli et al. 2004 found positivity 
in 35 of 48 (73%), Chu et al. 2002 in 88 of 96 (92%), Lee et al.. 2003 in 60 of 75 
(80%) and Wieczoreck et al. 2002 in 50 of 76 HCCs (66%). In our study, HepPar1 
was positive in all HCCs, as Siddiqui et al. 2001 have also reported. Although 
Wee 2006 and Wee et al 2003 reported that not all HepPar1-positive tumors are of 
hepatocytic origin or arise in liver, in our study HepPar1 was found to be 
negative in all cases of metastatic carcinomas with the exception of one 
cholangiocarcinoma that exhibited few positive cells with granular cytoplasmic 
staining. Other studies reported the same results Wang et al. 2006; Siddiqui et al. 2001. 
HepPar1 was shown to be an excellent immunocytochemical marker for HCCs 
on smeared cells with the same or even better accuracy compared with cell 
block material (range, 66-100%) Lugli et al. 2004; Lee et al. 2003; Chu et al. 2002; Wieczorek, et al. 
2002; Siddiqui et al. 2001.  
 
BerEP4 is a monoclonal antibody directed against a cell surface glycoprotein 
present in human epithelial cells. It is usually not present in hepatocytes and in 
the superficial layer of squamous epithelium. BerEP4 has been used in panels 
to differentiate adenocarcinomas from mesotheliomas Motherby et al. 1999; Latza et al. 
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1990. It is also included in immunohistochemical differentiation of HCC from 
metastatic carcinomas to the liver Murakata et al. 2000; Porcell et al. 2000; Ma et al. 1993; Latza et al. 
1990. In 1990, Latza et al. 1990 reported BerEP4 reactivity in 142 of 144 epithelioid 
tumors (99%) with exception of some HCCs. Murakata et al. 2000 and Porcell et 
al. 2000 found one of ten and one of 13 cases of HCC, respectively, with BerEP4 
rare and focal staining. These results differed somewhat from a previous study 
that demonstrated BerEP4 staining in 83% of metastatic carcinomas and 36% 
of HCCs Ma et al. 1993. We found only 33% of HCCs to be focally positive (score 1) 
with BerEP4, but it was strongly positive in all metastatic carcinomas and 
weakly positive in one case of malignant mesothelioma.  
 
-Fetoprotein is one of the earliest oncofetal markers developed and used 
frequently in the differential diagnosis of HCC from metastatic carcinomas 
Bedrossian et al. 1989. We found -fetoprotein positivity in 62% of HCCs studied. 
Previous reports have identified -fetoprotein positivity in 2% to 61.5% of this 
tumor Wang et al. 2006; Görög et al. 2005;Lugli et al. 2004; Lau et al. 2002; Porcell et al. 2000; Bedrossian et al. 
1989;. Some studies noted scarcity or absence of -Fetoprotein in metastatic 
carcinomas Wang et al. 2006; Lau et al. 2002; Porcell et al. 2000. 
 
The Ki-67 antibody recognizes a nuclear protein involved in the proliferation 
phase of the cell cycle Dabbs, 2006. We found Ki-67 expression > 30% in 89.5% of 
HCCs. Regenerative nodules demonstrated Ki-67 expression < 2%. De Jong et 
al. 1998 reported Ki-67 expression in liver metastases as low in 35%, intermediate 
in 22.5%, and high in 42.5%, and no proliferative activity in normal liver tissue. 
They grouped Ki-67 expression as low (<33%), high (>67%), and intermediate 
(between 33 and 67%). Quaglia et al. 2006 reported a statistically significant 
trend of increasing Ki-67 expression (P=.006) from regenerative nodules to 
HCC, showing 5.4% as a median percentage of cell expressing Ki-67 in HCC. 
 
CD68 was used to identify macrophages. It was expected that few or no 
macrophages would be found in HCCs and some in reactive cellular changes of 
regenerative nodules. There was no difference in CD68 positivity of HCC and 
metastatic carcinoma. The results of the current study are in agreement with 
previous observations Peng et al. 2005 demonstrating CD68 negativity in all HCCs. 
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Only a few cells were positive (score 0, < 10%) that should derive from 
surrounding liver tissue Bortolami et al. 2002. 
 
Capillarization of hepatic sinusoids is a well-recognized phenomenon that 
occurs in HCCs Pusztaszeri et al. 2006. CD31 is directed to PECAM-1, a cell-cell 
adhesion molecule of the immunoglobulin superfamily, expressed by most 
endothelial cells. Frachon et al. 2001 found CD31 expression of endothelial cells 
in 87% HCCs, whereas we found it in all of our cases of HCCs. 
 
We also investigated a panel of six different monoclonal antibodies and an 
algorithm for diagnostic interpretation of their staining results, to identify the 
primary sites of metastatic carcinomas that has previously been published 
Pomjanski et al. 2005 (Fig. 5). In 62 FNACs of the liver, the favoured primary tumor 
sites were correctly diagnosed in 90.3%. Using this same panel and another 
one when there was a cytomorphologic and/or clinical indication for metastatic 
neuroendocrine tumours (Fig. 6) in 30 FNACs of the lymph nodes, the favoured 
primary tumor sites were correctly diagnosed in 92.3%. 
 
The first step in the interpretation of immunocytochemical staining results was a 
comparative, semiquantitative evaluation of CK7 and CK20 reactions, as 
described in a previous study Pomjanski et al. 2005. The combination of a CK7 score < 
CK20 score with a CdX2 score 5, suggested a carcinoma of the colon. 
Reactions with a CK7 score > CK20 score and a TTF-1 score 1 to 5, was more 
typical for carcinomas of the lungs. The immunocytochemical marker 
combination of CK7 score that was equal to that of CK20 with CK5/6 score 1 to 
3 and CdX2 score 0 to 2, suggested a gastrointestinal carcinoma or a 
carcinoma of the pancreas. 
 
Cytokeratins (CK) represent the epithelial class of intermediate-sized filaments 
of the cytoskeleton. Analysing the expression of CK7 and CK20 has been found 
to be helpful in discriminating primary and metastatic tumor from different sites 
Varadhachary et al. 2004; Bugat et al. 2003; Pavlidis et al. 2003. A CK20 score > than the CK7 score 
was found in 71 to 100% of metastatic carcinomas of the colon to the liver Tot, 
2004; Lau et al. 2002; Rullier et al. 2000; Tot, 1999. Our result is consistent with these reports; 
91.7% of metastatic carcinomas of the colon to the liver demonstrated a CK20 
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score that was > than that of CK7, but all patients had CK20 positivity, which is 
in accordance with the findings of Rullier et al. 2000. In the current study, a CK7 
score > CK20 score was found in 100% of metastases from lung cancer, 
cholangiocarcinoma and pancreatic adenocarcinomas. CK5/6 was positive in 
50% of metastatic carcinomas of the stomach and pancreas in FNAC of the 
liver. In FNACs of lymph nodes, the combination of CK7 score < CK20 score 
with CdX2 score 5, suggested a carcinoma of the intestines. Reactions with 
CK7 score > CK20 score and TTF-1 score > 2, was more typical for carcinomas 
of the lungs in FNACs of lymph nodes.  
 
Cdx2 is a cloned caudal-type homeobox gene, encoding a transcription factor 
that plays an important role in proliferation and differentiation of intestinal 
epithelial cells Drummond et al. 1997. It is suggested to be useful in determining the 
site of origin for metastatic intestinal-type tumors, particularly colorectal 
adenocarcinomas De Lott et al. 2005. Barbareschi et al. 2003 reported 100% specificity 
and sensitivity of Cdx2 in detecting colorectal origin of metastases to the lung. 
However, somewhat in contrast, Tot 2004 found Cdx2 expression in 84% of 
metastases of colorectal carcinomas in core needle biopsies of the liver. We 
found similar results in the current study of FNACs of the liver: 85.7% of 
metastatic carcinomas of the colon were positive for Cdx2 (score > 2). Of these, 
67% demonstrated diffuse positivity with Cdx2 (score 5). In all three cases of 
carcinoma of the intestines from FNACs of lymph nodes, CdX2 demonstrated 
strong positivity (score 5). 
 
Thyroid transcription factor (TTF-1) belongs to the NK-2 family of homeodomain 
transcription factors, which is expressed selectively in the thyroid, lungs and 
central nervous system Bingle, 1997. In tumors originating from lung or thyroid 
tissue, the immunoreactivity typically is nuclear. Cytoplasmic staining has been 
reported in approximately 71 to 77% of HCCs Wieczorek, et al. 2002. Pan et al. 2004 
reported that 58% of HCCs revealed TTF-1 cytoplasmic immunoreactivity but, 
because of a discrepancy in TTF-1 immunoreactivity, they believe that 
cytoplasmic reactivity does not represent a genuine expression of TTF-1 protein 
in HCCs. We evaluated only nuclear expression. TTF-1 was negative in 
metastatic carcinomas from the breasts, pancreas, uterine cervix, stomach and 
in cholangiocarcinomas. It was positive in 50% of metastases originating from 
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the lungs. Roh & Hong 2002 found TTF-1 expression in 69% of metastases of 
lung carcinomas in tissue sections from lymph nodes. We had similar results in 
the current study, 66.7% of metastatic carcinomas of the lung were positive for 
TTF-1 (score > 2) applied on FNACs from lymph nodes. 
 
CA 125 was originally introduced as a marker of ovarian cancer that recognizes 
the CA 125 glycoprotein Nolan & Heatley 2001. Although CA 125 is most commonly 
present in gynaecologic adenocarcinomas, it is also produced by some 
adenocarcinomas arising from other sites, as the pancreas, bile ducts, breasts, 
lungs, thyroid, distal oesophagus/stomach and liver Loy et al. 1992. We found CA 
125 positivity (score 4) only in one case of ovarian carcinoma. It was negative 
for all other sites of metastatic adenocarcinomas in FNACs of the liver. 
 
In three cases, the clinician suspected metastatic neuroendocrine tumors to the 
liver. To confirm this suspicion, we used chromogranin A and synaptophysin, 
neuroendocrine markers that demonstrated positivity (score > 4). This result is 
in agreement with other studies Khalbuss et al. 2005; Gupta et al. 2000. In two cases, 
malignant melanoma was suspected by the clinician and we used HMB-45, a 
melanocyte-specific antibody that recognizes gp100, a component of the 
melanosomal complex Zubovits et al. 2004. The metastatic cells revealed a strong 
positivity with this marker (score 5), in accordance with other studies Khalbuss et al. 
2005; Caturelli et al. 2002. PSA was positive (score 3) in one case of suspected prostate 
carcinoma. 
 
Some authors Wang et al. 2006; Lugli et al. 2004; Lau et al. 2002; Porcell et al. 2000; Rishi et al. 1994, have 
reported the use of pCEA, mCEA, CD10 and other antibodies to differentiate 
HCC from metastatic carcinoma or regenerative nodules using 
immunohistochemical panels in paraffin-embedded cell blocks. Our study is 
based on the use of immunocytochemical panels applied on the identical slides 
used for cytological diagnosis, using a limited number of antibodies for specific 
cytomorphological suspicious. Thus, compared with application on histological 
sections, only a restricted number of antibodies can be applied to a usually 
limited number of smears from FNACs. We therefore concentrated on a few 
markers only that, as demonstrated by our results, are achieved to reach a 
reasonable diagnostic accuracy. 
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To distinguish non-Hodgkin lymphoma (NHL) from metastatic carcinoma in 
FNAC of lymph nodes, we used BerEP4 and LCA, and achieved a corrected 
diagnosis in 100%. In seven cases of metastatic carcinomas, BerEP4 was 
positive (score > 2) and negative in one case of NHL. The leucocyte common 
antigen (LCA), also known as CD45, is a cell surface glycoprotein complex that 
is selectively expressed on all haematopoietic cells, excluding mature erythroid 
and megakaryocytic cells. Thus, the use of an antibody to LCA is generally 
considered to be a universal marker for all leucocyte cell types Streuli et al. 1988. In 
one case of B-cell NHL, LCA was highly positive (score 5), while it was negative 
in all cases of metastatic carcinomas. Our results are in concordance with other 
studies Dey, 2006; Gupta et al. 2003a; Gupta et al. 2003b. 
 
To identify a suspected metastatic neuroendocrine tumor after preliminary 
cytomorphological and clinical information of FNAC of the lymph nodes, we 
tested an algorithm analysing BerEP4 and LCA reactions, to exclude a 
lymphoma. When BerEP4 was positive (score > 2) and LCA negative (score 0), 
we favoured a neuroendocrine tumor. To reinforce this diagnosis, we awaited 
TTF1 positivity with score > 2, CD56 with score > 3, chromogranin A with score 
> 2 and synaptophysin with score > 2. When BerEP4 was negative and LCA 
positive (score > 3), we favoured a lymphoma and applied the 
immunocytochemical antibodies for NHL.  
 
CD56, a neural cell adhesion molecule, belongs to a family of cell surface 
sialoglycoproteins of the immunoglobulin superfamily Rutishauser et al. 1988. CD56 is 
expressed on the surface of the vast majority of the cells of pulmonary small cell 
carcinomas (SCLC) (Fig. 9), it is therefore considered the most useful and 
sensitive marker for this tumor Kontogianni et al. 2005. Kontogianni et al. 2005 reported a 
strong positive staining for CD56 in 100% of SCLC. In the current study, CD56 
demonstrated relative high positivity (score > 3) and TTF-1 score > 2. 
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Figure 9: Metastatic cells stained by CD56 in metastatic neuroendocrine tumor. (400X) 
 
Chromogranin A is a monomeric protein with 75kD weight that composes the 
major portion of the soluble protein extract of neurosecretory granules of 
neuroendocrines cells. Synaptophysin is a glycoprotein that is an integral part of 
the neuroendocrine secretory granule membrane and is recognized by 
monoclonal antibody (SY38) in a variety of neuroendocrine tumors Dabbs, 2006. De 
Las Casas et al. 2004 used chromogranin and synaptophysin to confirm the 
diagnosis of small-cell carcinoma in fine-needle aspiration biopsy material from 
lymph node. In the current study, chromogranin and synaptophysin were 
positive in a considerable number of cells (score > 2) of metastatic 
neuroendocrine tumors.  
 
The role of FNAC in diagnosing lymphoma remains controversial. Even when 
FNAC identifies lymphoma, it can be difficult to classify the type of lymphoma 
necessary for optimal treatment. Hehn et al. 2004 concluded in their study that 
fine-needle aspiration for diagnosing lymphoma may even misguide treatment. 
Despite the shortcoming of FNAC for the classification of lymphomas, it remains 
the best initial diagnostic test for the triage of lymph nodes, because most 
enlarged lymph nodes at the primary care level are benign Floretine et al. 2006. 
 
In the current study the number of lymphomas was too small (n=8) to establish 
an algorithm similar to that published for metastatic tumors Pomjanski et al. 2005. We 
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currently only intend to differentiate Hodgkin- from non-Hodgkin lymphomas and 
B- from T-cell lymphomas. We used LCA to confirm the lymphoma diagnosis 
that demonstrated high positivity (score > 3) in our cases of NHL (Fig.10). To 
classify B-cells, we used CD 20 and CD79a, that demonstrated score > 4 and    
> 2, respectively. The CD20 epitope is acquired late in the pre B-cell stage of 
maturation, and remains on cells throughout most of their differentiation, 
although it is lost at the plasma cell stage Dabbs, 2006. CD79a is associated with 
the immunoglobulin molecule; it is expressed early in ontogeny and is used to 
detect B-cells, showing no staining of T-cells Mason et al. 1995. We did not have T-
cell lymphomas in our study, but we used CD45Ro as T-cell marker that 
revealed no reaction (score 0) in two cases of NHL of B-cell type. CD45Ro is a 
membrane protein thyrosine phosphatase localized to myeloid and T cells Dabbs, 
2006.  
 
 
Figure 10: Lymphatic cells from FNAC of lymph nodes stained by LCA (400X).  
 
 
In one case of FNAC of lymph node we suspected a Hodgkin Lymphoma (HL) 
due high positivity (score 4) for CD15 and CD30, but the histological follow up 
rendered a NHL. CD15 and CD30 are recognized as markers for the Reed-
Sternberg cells of classical HL Zhang et al. 2006; Dabbs, 2006; Jogai et al. 2006.  
 
Another application of immunocytochemistry in the current study could support 
the cytologic interpretation of clinically suspected metastatic carcinomas that 
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were correctly diagnosed in 100%. CD56 and TTF-1 were used in three cases 
of a neuroendocrine tumor. TTF-1 was used as a useful adjunct to CD56 in the 
diagnosis of SCLS Kontogianni et al. 2005. In our three cases, CD56 showed high 
positivity (score 4) and TTF-1 score > 2. 
 
To confirm the suspicion of NHL in three cases, we found Ki-67 positivity in > 
50% of lymphatic cells and BCL-2 in some of these cells (score 2). The Ki-67 
antibody recognizes a nuclear protein involved in the proliferation phase of the 
cell cycle Dabbs, 2006. Dey 2006 used Ki-67 and BCL-2 in an immunocytochemical 
panel to classify NHLs on FNACs, while Young 2006 and Sun 2004 used them to 
determine the grade of malignancy of lymphomas.  
 
PSA was applied in two cases suspected of metastatic prostate carcinomas. 
PSA is a 34 kD single-chain glycoprotein of 237 amino acids produced almost 
exclusively by prostatic epithelial cells Dabbs, 2006. It demonstrated positivity in a 
considerable number of abnormal cells. Murray et al. 2004 and Gupta et al. 2003a 
also found strong positivity to only traces of PSA staining in all cases of 
metastatic prostate carcinomas in FNACs.  
 
CD138, a marker for plasma-cells Ng et al. 2006, was positive in the majority of cells 
(score 5) from a suspected metastatic plasmocytoma. RCC, a marker with high 
specificity for renal cell carcinomas Gokden et al. 2003, was positive (score 2) in one 
case suspected of renal carcinoma. Uroplakin III, a highly specific antibody for 
transitional epithelium Dabbs, 2006; Parker et al. 2003, demonstrated positivity (score 2) in 
one case suspected of bladder cancer. In one case suspicious for malignant 
melanoma, S100 and HMB-45 demonstrated positivity (score 2). CA15-3 
revealed high positivity (score 5) in one case suspected breast carcinoma. 
Huang et al. 2004 reported 91% of breast cancers with positive reaction to CA15-
3. In one case of suspected squamous cell carcinoma of the lung, CK7 and 
CK1,10,11 were positive in the majority of cells, while CK20 and TTF-1 were 
negative. In one case suspected of pancreatic carcinoma, we applied BerEP4 to 
confirm an epithelial tumor, that demonstrated to be highly positive (score 5), 
LCA (to exclude lymphoma) and chromogranin A and synaptophysin (to exclude 
small cell carcinoma) revealed no cellular reaction (score 0). 
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More than two decades have passed since immunocytochemistry was first 
successfully applied to cytologic specimens, but its impact on diagnostic 
cytology so far is not yet as strong as in histology. There are scarce studies 
concerning immunocytochemistry used in previously stained, routine cytologic 
smears. Mitteldorf et al. 1999 stated that alcohol preserves the cytoskeletal 
filaments much better than an additive fixation with formaldehyde derivates. 
Such differences in fixatives make immunocytochemistry easier in previously 
stained screened smears and thus more conclusive than if applied to cell 
blocks.  
 
The use of routinely prepared and previously stained smears offers many 
advantages over sections from cell blocks since it allows conventional 
microscopic examination, prior to immunocytochemical staining, and the 
selection of suitable smears or even groups of microscopically classified cells 
for further investigation. It is a simple technique and provides good antigen 
preservation.  
 
In conclusion, FNAC of the liver and of enlarged lymph nodes is a safe, low-cost 
and effective diagnostic procedure. The application of immunocytochemical 
staining contributes to a definitive diagnosis that could be achieved on the same 
routinely prestained cytologic slides used for microscopic diagnosis. This study 
analyzed the performance of immunocytochemistry to overcome 
cytomorphological difficulties and support the cytological interpretation in 
FNACs of the liver and lymph nodes. It analyzed the performance of a panel of 
six monoclonal antibodies (HepPar1, -Fetoprotein, BerEP4, CD31, CD68 and 
Ki-67) in differentiating HCC from metastatic carcinoma or regenerative nodules 
in FNACs of the liver with diagnostic accuracy of 100%. Another analysis was 
done with a panel of six different monoclonal antibodies (CK5/6, CK7, CK20, 
CA125, TTF-1 and Cdx2) to identify the primary sites of metastatic carcinomas 
in FNACs of the liver with 90.3% diagnostic accuracy. Using this same panel 
with another one (BerEP4, LCA, TTF1, CD56, Chromogranin A and 
Synaptophysin) when there was a suspicion of metastatic endocrine tumors in 
FNACs of the lymph nodes, we obtained 92.3% of diagnostic accuracy. 100% 
diagnostic accuracy was found to differentiate NHL from metastatic carcinoma 
using BerEP4 and LCA and to confirm a clinical suspicion of a specific 
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metastatic carcinoma, using different markers according to a clinical proposal in 
FNAC of lymph nodes. All results were confirmed by histology and/or clinical 
follow up. 
 
The finding that the tumor sites proposed by immunocytochemistry from their 
metastasis was correct in 90.3% of FNACs of the liver and 92.3% of lymph 
nodes, means, in practice, that clinicians could immediately focus at the 
mentioned organs and thus save radiological, endoscopic or surgical 
explorations in less probable regions of the body. Therefore, relevant economic 
benefits may result and save patients from unnecessary and unpleasant 
diagnostic procedures. 
 
The panels studied could be a useful tool in the diagnostic routine assessment 
of FNACs of the liver to discriminate HCCs from metastatic carcinomas or 
regenerative nodules, and especially for the identification of primary sites of 
metastatic carcinomas of FNAC of the liver and lymph nodes.  
 
Although most investigations in the literature applied antibodies on cell block 
material, we demonstrated that immunocytochemistry can also be performed 
directly on smeared and routinely prestained cells, with reasonable results. 
Their performance should be confirmed in a larger series of cases. 
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BACKGROUND: Difficulties with cytologic diagnoses on FNACs of coin-lesion 
in the liver and of enlarged lymph nodes can be overcome by the application of 
immunocytochemical panels applied on smears. The aim of this study was to 
investigate the performance of different panels of monoclonal antibodies in 
FNACs of the liver for: 1) the differentiation of hepatocellular carcinoma (HCC) 
from metastatic carcinoma (MC); 2) the identification of the primary sites of MC 
to the liver; and in FNACs of lymph nodes for: 3) the identification of the primary 
sites of MC and confirm a cytological and/or clinical suspicion for a metastatic 
neuroendocrine carcinoma; 4) to differentiate non-Hodgkin lymphoma (NHL) 
from MC, 5) to confirm a clinical suspicion of a specific primary tumor site, and 
6) to try a classification of malignant lymphomas. 
 
METHODS: In a validating cohort study, all patients had confirmatory 
histological and/or clinical follow up. 108 FNACs of coin lesions of the liver and 
64 of lymph nodes were routinely evaluated applying immunocytochemistry as 
an ancillary method. 23 HCCs were analysed for the distinction from metastatic 
carcinoma applying a panel of HepPar1, -Fetoprotein, BerEP4, CD31, CD68 
and Ki67. 85 cases of unknown primary tumors metastatic to the liver and 30 to 
the lymph nodes were analysed to investigate the suitability of a marker panel 
consisting of CK5/6, CK7, CK20, CA125, TTF1, and Cdx2, BerEP4, LCA, TTF1, 
CD56, Chromogranin A and Synaptophysin were used when there was a 
cytological and/or clinical suspicion for a metastatic neuroendocrine carcinoma. 
10 FNACs of lymph nodes were analysed for the differentiation of Non Hodgkin 
Lymphoma (NHL) from MC, applying BerEp4 and LCA. Using PSA, CD138, 
RCC, LCA, Uroplakin III, S100, HMB-45, CA15-3, Chromogranin A and 
Synaptophysin, 16 cases were checked to confirm the clinical suspicion of a 
specific primary tumor site from lymph nodes metastasis. Finally we tried to 
classify 8 suspicious cases of malignant lymphomas applying LCA, CD20, 
CD79a, CD45Ro, CD15 and CD30. 
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RESULTS: Applying immunocytochemistry as an adjuvant method to cytological 
smears the following diagnostic accuracy could be reached: 1) 100% for the 
differentiation of HCC from MC; 2) 90.3% for the identification of primary tumor 
sites from their metastases to the liver in FNACs from coin lesions; 3) 92.3% for 
the identification of primary tumor site from their metastases to lymph nodes in 
FNACs; 4) 100% for the differentiation of NHL from MC; 5) 100% to confirm a 
clinical suspicion of a specific MC to lymph nodes; and 6) 87.5% for typing of 
NHL. In 23 cases of carcinoma of unknown primary in FNACs of the liver and 7 
of lymph nodes, the site of the primary tumor remained clinically unknown.  
 
CONCLUSIONS: Application of immunocytochemical panels on the same slide 
used for microscopic diagnosis is a useful tool in the routine assessment of 
FNACs of the liver to discriminate HCCs from MC and for the identification of 
primary tumor sites of MC to the liver. It can also contribute to the routine 
assessment of FNACs of lymph nodes to discriminate NHL from MC, to confirm 
a clinical suspicion of a specific MC, and for the identification of primary sites of 
MC to the lymph nodes. Their performance should be confirmed in a larger 
series of cases. 
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HINTERGRUND: Die Zytologische Diagnostik an FNABs (Feinnadelaspirations-
Biopsien) der Leber und vergrößerten Lymphknoten ist gelegentlich mit 
diagnostischen Schwierigkeiten behaftet. Diese können durch die Anwendung 
eines immunzytochemischen Panels an den vorgefärbten Abstrichen 
überwunden werden. Ziel der Studie war es, die differentialdiagnostischen 
Möglichkeiten unterschiedlicher Panels monoklonaler Antikörper zu analysieren: 
Erstens zur Abgrenzung des hepatozellulären Karzinoms (HCC) von 
Karzinommetastasen oder gutartigen Regenerat-Knoten an der Leber, zweitens 
zur Bestimmung des wahrscheinlichen Primärtumors bei Karzinommetastasen 
von Leber und Lymphknoten, drittens zur Bestätigung eines zytologischen 
und/oder klinischen Verdachts auf einen metastasierten neuroendokrinen 
Tumor von Lymphknoten, viertens Unterscheidung zwischen non-Hodgkin 
Lymphomen (NHL) und Karzinommetastasen, fünftens zur Bestätigung einer 
Primärtumor-Lokalisation bei entsprechendem klinischen Verdacht, und 
sechstens zur Klassifikation maligner Lymphome. 
 
METHODEN: Im Rahmen einer validierenden Kohortenstudie wurden alle 
zytologischen Diagnosen durch eine histologische Diagnose und/oder klinische 
Nachuntersuchungen abgeklärt. 108 FNABs von Raumforderungen der Leber 
und 64 von Lymphknoten aus der Routindiagnostik des Instituts für 
Cytopathologie wurden zusätzlich mittels Immunzytochemie untersucht. 23 
HCCs wurden zur Unterscheidung von Karzinommetastasen oder von 
gutartigen Regenerat-Knoten unter Anwendung der Marker HepPar1, - 
Fetoprotein, BerEP4, CD31, CD68 und Ki67 immunzytochemisch markiert. 85 
Patienten mit Lebermetastasen und 30 mit Lymphknotenmetastasen, bei denen 
der Primärtumor zum Untersuchungszeitpunkt unbekannt war, wurden 
immunzytochemisch unter Anwendung der Marker CK5/6, CK7, CK20, CA125, 
TTF1 und Cdx2 untersucht, um den wahrscheinlichen Primärtumor zu 
identifizieren. Die Marker BerEP4, LCA, TTF1, CD56, Chromogranin A und 
Synaptophysin wurden bei einem zytologischen und/oder klinischen Verdacht 
auf einen metastatisierten neuroendokrinen Tumor verwendet. Zehn FNABs 
von Lymphknoten wurden zur Unterscheidung von non-Hodgkin Lymphomen 
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(NHL) von Karzinommetastasen mit BerEp4 und LCA markiert. Mit 
unterschiedlichen Antikörpern (PSA, CD138, RCC, LCA, Uroplakin III, S100, 
HMB-45, CA15-3, Chromogranin A und Synaptophysin), wurden Biopsien von 
16 Patienten überprüft, um den klinischen Verdacht auf einen spezifischen 
Primärtumor zu bestätigen. Schließlich wurde versucht, acht Verdachtsfälle 
maligner Lymphome mittels LCA, CD20, CD79a, CD45Ro, CD15 und CD30 zu 
klassifizieren. 
 
ERGEBNISSE: Die Treffsicherheit von FNABs der Leber zur Unterscheidung 
eines HCC von Karzinommetastasen oder gutartige Regenerat-Knoten lag bei 
100%. Sie betrug 90.3% zur Bestimmung der Primärtumor-Lokalisation bei 
metastasierten Karzinomen. Bei FNABs von Lymphknoten betrug die Sicherheit 
zur Unterscheidung eines NHL von Karzinommetastasen 100%, 92.3%, um die 
wahrscheinliche Primärtumor-Lokalisation metastasierender Karzinome zu 
bestimmen, und 100%, um einen spezifischen klinischen Verdacht bei 
Karzinommetastasen zu bestätigen. Die Klassifikation maligner Lymphome 
gelang in 87.5%. Bei 23 FNABs der Leber und sieben von Lymphknoten blieb 
die Lokalisation des Primärtumors auch nach der immunzytochemischen 
Färbung unbekannt.  
 
SCHLUSSFOLGERUNGEN: Die immunozytochemische Anwendung eines 
Antikörper-Panels an denselben Ausstrichen wie für die zytologische 
Routinediagnostik, ist ein nützliches Verfahren bei FNABs der Leber, um HCCs 
von Karzinommetastasen oder gutartigen Regenerat-Knoten zu unterscheiden 
und um den Primärtumor bei metastasiertem Karzinom zu identifizieren. Bei 
FNABs von Lymphknoten, dient sie dazu ein NHL von Karzinommetastasen zu 
unterscheiden, ggf. einen spezifischen klinischen Verdacht bei metastasiertem 
Karzinom zu bestätigen und um den Primärtumor bei metastasiertem Karzinom 
zu identifizieren. Diese Ergebnisse sollten an größeren Patientenkollektiven 
bestätigt werden. 
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